These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27914873)

  • 1. Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer.
    Sidana A; Kadakia M; Friend JC; Krane LS; Su D; Merino MJ; Srinivasan R
    Urol Oncol; 2017 Mar; 35(3):114.e9-114.e14. PubMed ID: 27914873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
    Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
    Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
    Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
    Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma.
    Keskin S; Keskin Z; Taskapu HH; Kalkan H; Kaynar M; Poyraz N; Toy H
    BMC Urol; 2014 Nov; 14():95. PubMed ID: 25427576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.
    Rosenkrantz AB; Sekhar A; Genega EM; Melamed J; Babb JS; Patel AD; Lo A; Najarian RM; Ahmed M; Pedrosa I
    Eur Radiol; 2013 Feb; 23(2):579-87. PubMed ID: 22903703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
    Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
    Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma.
    Gao J; Agizamhan S; Zhao X; Jiang B; Qin H; Chen M; Guo H
    Future Oncol; 2019 May; 15(13):1459-1468. PubMed ID: 30977386
    [No Abstract]   [Full Text] [Related]  

  • 13. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
    Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma.
    Le X; Wang XB; Zhao H; Chen RF; Ge P
    BMC Urol; 2020 Sep; 20(1):148. PubMed ID: 32933514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
    Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
    PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management.
    Ren W; Gao X; Zhang X; Hu J; Li H; Zu X
    Clin Transl Oncol; 2020 May; 22(5):725-733. PubMed ID: 31317521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
    Hamilton Z; Lee HJ; Jimenez J; Lane BR; Wang S; Beksac AT; Gillis K; Alagh A; Tobert C; Randall JM; Kane CJ; Millard F; Campbell SC; Derweesh IH
    BJU Int; 2016 Dec; 118(6):927-934. PubMed ID: 27008916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.